22:02 , Dec 9, 2016 |  BC Week In Review  |  Company News

Abbott, Alere deal

Abbott filed a lawsuit in the Delaware Court of Chancery seeking to terminate its proposed acquisition of Alere for about $5.8 billion, alleging a "substantial loss in Alere's value" since the companies signed the deal...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Alere i RSV test regulatory update

FDA granted 510(k) clearance to Alere i RSV test from Alere to detect respiratory syncytial virus (RSV) infection. Alere said the test, which detects RSV from nasopharyngeal swab samples using isothermal nucleic amplification technology, would...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Alere, Abbott deal

Abbott will acquire diagnostics company Alere for $56 per share in cash, or about $5.8 billion. The price is a 50.5% premium to Alere’s close of $37.20 on Jan. 29, the last trading day before...
02:48 , Feb 2, 2016 |  BC Extra  |  Company News

Abbott buys diagnostics company Alere

Abbott Laboratories (NYSE:ABT) is acquiring diagnostics play Alere Inc. (NYSE:ALR) for $56 per share in cash, or about $5.8 billion. Abbott said it will assume or refinance Alere's net debt of $2.6 billion. The acquisition...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Alere i Strep A test regulatory update

FDA granted a CLIA waiver to Alere i Strep A test to detect group A Streptococcus bacteria in throat swab specimens. FDA approved the isothermal nucleic acid-based test in April. Alere Inc. (NYSE:ALR), Waltham, Mass....
07:00 , Jun 15, 2015 |  BC Week In Review  |  Financial News

Alere completes private placement of senior notes

Alere Inc. (NYSE:ALR), Waltham, Mass.   Business: Diagnostic   Date completed: 2015-06-11   Type: Private placement of senior notes   Raised: $425 million   Investor: Institutional investors   Note: The senior subordinated unsecured notes bear 6.375% interest and mature in 2023....
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

Alere q HIV-1/2 Detect regulatory update

Alere received CE Mark approval for Alere q HIV-1/2 Detect assay to detect and identify and distinguish between HIV-1 subgroup M/N and O and HIV-2 infection in under 60 minutes using a blood sample from...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Alere Inc, Qiagen deal

Qiagen purchased circulating tumor cell (CTC) detection technology and two diagnostics -- AdnaTest BreastCancer and AdnaTest Prostate Cancer -- from Alere’s AdnaGen GmbH subsidiary. AdnaTest BreastCancer is a breast cancer diagnostic that uses RT-PCR...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Qiagen N.V, Tokai deal

Qiagen and Tokai partnered to co-develop a liquid biopsy circulating tumor cells (CTCs) companion diagnostic. The diagnostic will be used with Tokai’s galeterone, a selective androgen receptor modulator (SARM) and cytochrome P450 17 alpha-hydroxylase/C17,20...
01:54 , Mar 24, 2015 |  BC Extra  |  Company News

Management tracks

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) appointed Timothy Wright as EVP of business development, strategy and innovation, effective April 13. Wright was director of the Drug Discovery and Development Institute at The Ohio State University Comprehensive...